Breakthrough Cancer Research Donate

Evaluating anti-neoplastic activity of HDAC6 inhibitors in uveal melanoma cells and in zebrafish patient-derived uveal melanoma xenograft models

Posted on: 14 Oct 2020

Evaluating anti-neoplastic activity of HDAC6 inhibitors in uveal melanoma cells and in zebrafish patient-derived uveal melanoma xenograft models
Dr Husvinee Sundaramurthi

Start year: 2020

Principal Investigator: Prof Breandán N Kennedy

Institution: UCD Conway Institute, University College Dublin

Grant funding: Irish Research Council Enterprise Partnership Scheme (Postdoctoral) grant with Breakthrough cancer Research as the Enterprise Partner

Linked Breakthrough Research Priorities: 1, 2, 3, 4, 5

Patients diagnosed with primary eye cancer or uveal melanoma (UM) have poor survival. Furthermore, approximately 50% will suffer from metastatic UM with a median overall survival of 4 to 15 months, with approximately 15% of patients making it to the one-year mark. Within Ireland, it is estimated that the incidence rate of UM per capita is 1.3 cases/100,000 yearly, higher than in the UK or USA.

Current treatment options are surgical removal of the eye and combined radiation therapy. Hence, there is an imperative need to identify novel drugs to treat uveal melanoma. Histone deacetylase 6 inhibitors (HDAC6i) have shown great promise as an anti-neoplastic agent and are currently under clinical trial investigations for other cancers. The goal of this study is to: 1) identify the capability of HDAC6i to prevent UM tumor growth and 2) understand how HDAC6i works to prevent UM tumor growth.  It is hoped that this study will lead to new therapies for UM.

© Site Designed by Granite Digital